HOME
ABOUT MORSE
The Team
Strategic Partners
Lorraine Boyle
Dominika Dabrowski
Stephen Filbey
Brent Korte
Careers
SERVICES
Our Services
Strategic Advice
MORSE HTA Strategic Advice
Analyses
Advisory Boards
MORSE Advisory Panel (MAP)
Training
Private Payer
Negotiation Simulation
Reimbursement Training
Reports
Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
Oncology and Biosimilar Sub-Report
NEWS
MORSE Signals
MORSE Wire
Publications
What’s New
EVENTS
LINKS
CONTACT US
HOME
ABOUT MORSE
The Team
Strategic Partners
Lorraine Boyle
Dominika Dabrowski
Stephen Filbey
Brent Korte
Careers
SERVICES
Our Services
Strategic Advice
MORSE HTA Strategic Advice
Analyses
Advisory Boards
MORSE Advisory Panel (MAP)
Training
Private Payer
Negotiation Simulation
Reimbursement Training
Reports
Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
Oncology and Biosimilar Sub-Report
NEWS
MORSE Signals
MORSE Wire
Publications
What’s New
EVENTS
LINKS
CONTACT US
Market Access News
All the posts published.
pCPA Negotiation Status Update January 2019 – Two Oncology Negotiations Closed without LOI
February 14, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis
January 24, 2019
-
Market Access News
,
Publications
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Process Timelines Highlights – A Year-in-Review Primer
January 15, 2019
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Complete its Most Active Month by Adjudicating 15 Files in November
December 20, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
International Experience with Pharmaceutical Managed Entry Agreements
December 13, 2018
-
Market Access News
,
Publications
-
Posted by
MORSE Team
Read More →
Read More →
BC Pharmacare Now Transitioning Patients on Copaxone® to GLATECT™
November 29, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Number of Active pCPA Negotiations at an All-Time High and Continues to Climb
November 19, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Significant Developments in Canadian Drugs for Rare Disease Policy
November 14, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Presidents’ Roundtable – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
November 8, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Summary of the CADTH Drug Portfolio Information Session Nov. 2018
November 7, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Patient Support Programs – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
November 1, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
pCPA Panel – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
October 25, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Has RWE in Canada Reached a Tipping Point?
October 23, 2018
-
Market Access News
-
Posted by
Lorraine Boyle
Read More →
Read More →
HTA Panel – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
October 18, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Summary of the HC-HTA Alignment Webinar Sept. 2018
October 17, 2018
-
Market Access News
-
Posted by
MORSE Team
Read More →
Read More →
Older posts
Newer posts
Browse our Market Access News section - Page 5 of 10 - MORSE Consulting Inc.
Private
Public
Private
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB
Public
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB
Public
Private
Public
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB
Private
INESSS
CADTH
HTA
pCPA
Public Payers
Health Canada
Patients
Private Payers
PMPRB